-
Treating Cancer Based on Its Genetics, Not Its Location
Medical oncologist and sarcoma specialist George D. Demetri explains the significance of the recent approval of the oral drug Vitrakvi based on tumor genetics.
by Anna Azvolinsky
-
An Uncommon Partnership
Through the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.
by Ashley P. Taylor
-
The Genetics of Metastatic Cancer
The multiple tumors in patients with metastatic disease share key genetic traits, a sequencing study shows.
by Anna Azvolinsky
-
Paying for Tumor Testing
A recent U.S. government decision about coverage of tumor sequencing could affect cancer patients.
by Brad Jones
-
The Ins and Outs of Tumor Testing
In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.
by Kate Yandell
-
A New Type of Drug Approval
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
A Better Way to Screen for Lynch Syndrome?
Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
Previous |
Cancer Talk
Fixing Systems, Building Trust
The AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved explores efforts needed to address inequities in care and outcomes.
by Eric Fitzsimmons
Accelerating and Improving Drug DiscoveryForum for patient advocates explores how researchers are working to develop cancer treatments in a quicker, more efficient manner.
by Thomas Celona
Advanced Care Planning Leads to More Comfort-based CarePreparing for future health decisions helps ensure care is suited to your priorities.
by Karon Warren
Drop in Cancer Diagnoses Under COVID-19 Raises AlarmsResults of a recent study support concerns that pandemic disruptions resulted in finding fewer cancers.
by Kyle Bagenstose